O
Olga Mulas
Researcher at University of Cagliari
Publications - 42
Citations - 353
Olga Mulas is an academic researcher from University of Cagliari. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 8, co-authored 24 publications receiving 221 citations.
Papers
More filters
Journal ArticleDOI
Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
Monica Bocchia,Anna Sicuranza,Elisabetta Abruzzese,Alessandra Iurlo,Santina Sirianni,Antonella Gozzini,Sara Galimberti,Lara Aprile,Bruno Martino,Patrizia Pregno,Federica Sorà,Giulia Alunni,Carmen Fava,Fausto Castagnetti,Luca Puccetti,Massimo Breccia,Daniele Cattaneo,Marzia Defina,Olga Mulas,Claudia Baratè,Giovanni Caocci,Simona Sica,Alessandro Gozzetti,Luigiana Luciano,Monica Crugnola,Mario Annunziata,Mario Tiribelli,Paola Pacelli,Ilaria Ferrigno,Emilio Usala,Nicola Sgherza,Gianantonio Rosti,Alberto Bosi,Donatella Raspadori +33 more
TL;DR: This cross-sectional study provides the first evidence that “circulating” CML LSCs persist in the majority of CML patients in molecular response while on TKI treatment and even after TKI discontinuation.
Journal ArticleDOI
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients.
Giovanni Caocci,Bruno Martino,Marianna Greco,Elisabetta Abruzzese,Malgorzata Monika Trawinska,Sara Lai,Paola Ragatzu,Sara Galimberti,Claudia Baratè,Olga Mulas,Claudia Labate,Roberto Littera,Carlo Carcassi,Carlo Gambacorti Passerini,Giorgio La Nasa +14 more
TL;DR: KIR genotypes could prove useful in identifying patients that are likely to maintain MR(4.5) after discontinuing TKI treatment, and younger age, Bx haplotype, and the combination KIR3DS1/KIR3DL1 present/HLA-Bw4 present were significantly associated with relapse.
Journal ArticleDOI
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Giovanni Caocci,Olga Mulas,Elisabetta Abruzzese,Luigiana Luciano,Alessandra Iurlo,Immacolata Attolico,Fausto Castagnetti,Sara Galimberti,Nicola Sgherza,Massimiliano Bonifacio,Mario Annunziata,Antonella Gozzini,Ester Orlandi,Fabio Stagno,Gianni Binotto,Patrizia Pregno,Claudio Fozza,Malgorzata Monika Trawinska,Fiorenza De Gregorio,Daniele Cattaneo,Francesco Albano,Gabriele Gugliotta,Claudia Baratè,Luigi Scaffidi,Chiara Elena,Francesca Pirillo,Emilia Scalzulli,Giorgio La Nasa,Robin Foà,Massimo Breccia +29 more
TL;DR: Patients were stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels, and patients' AOEs were identified.
Journal ArticleDOI
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Giorgio La Nasa,Giovanni Caocci,Roberto Littera,S Atzeni,Adriana Vacca,Olga Mulas,Marzia Langiu,Marianna Greco,Sandro Orru,N Orru,Andrea Floris,Carlo Carcassi +11 more
TL;DR: It is suggested that a decrease in properly stimulated and activated NK cells might contribute to the occurrence of CML and homozygosity for KIR haplotype A as a promising immunogenetic marker of complete molecular response that could help clinicians decide whether to withdraw treatment in patients with CML.
Journal ArticleDOI
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
Giovanni Caocci,Olga Mulas,Mario Annunziata,Luigiana Luciano,Massimiliano Bonifacio,Ester Orlandi,Patrizia Pregno,Sara Galimberti,Antonella Russo Rossi,Elisabetta Abruzzese,Alessandra Iurlo,Bruno Martino,Nicola Sgherza,Gianni Binotto,Fausto Castagnetti,Antonella Gozzini,Claudio Fozza,Monica Bocchia,Anna Sicuranza,Fabio Stagno,Fabio Efficace,Emilio Usala,Fiorenza De Gregorio,Luigi Scaffidi,Chiara Elena,Francesca Pirillo,Claudia Baratè,Malgorzata Monika Trawinska,Daniele Cattaneo,Claudia Labate,Gabriele Gugliotta,Matteo Molica,Giorgina Specchia,Giorgio La Nasa,Robin Foà,Massimo Breccia +35 more
TL;DR: A large real-life cohort of Italian patients with CML treated with a 2TKIs as firstor subsequent-line of treatment was analyzed to evaluate the incidence of CV AEs and the association with the SCORE assessment and other baseline risk factors and the role of primary prophylaxis in preventing CV atherothrombotic events.